Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.

Also called NCT05557942

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
Aerovate Therapeutics (from the registry)
Registry
  • NCT NCT05557942
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Latvia, Mexico, Poland, Portugal, Singapore, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05557942. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-02 (actual); primary completion 2024-08-08 (actual). Results posted on 2024-10-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
Acronym
IMPAHCT-FUL
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
AV-101
Lead sponsor
Aerovate Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct05557942
Content hash
b5e4573770d0ac2c640e0b55d991c22e17d9a80d9820c66de3ced1a00bd391d2